Practice
Featured experience
Trial victory for ExxonMobil in tax litigation
We secured a decision affirming ExxonMobil’s entitlement to significant interest expense deductions arising out of a multi…
Non-custodial sentence for former Fiat Chrysler engineer in emissions case
We represented the defendant in a criminal prosecution and secured a time-served sentence
Trial victory for Comcast in patent litigation brought by WhereverTV
We secured a ruling of no infringement on behalf of Comcast
Rare dismissal of criminal antitrust charge against chicken supply executive
We secured the dismissal of price-fixing and bid-rigging charges brought by the DOJ Antitrust Division against Jason McGuire
Morgan Stanley $7 billion acquisition of Eaton Vance
Davis Polk is advising Morgan Stanley on its $7 billion acquisition of Eaton Vance Corp. The acquisition is subject to…
ADIA investment in Reliance Industries’ Reliance Retail Ventures
Davis Polk is advising Reliance Industries Limited and Reliance Retail Ventures Limited in connection with the Abu Dhabi…
Perfect Achiever Group HK$1.34 billion acquisition of Macau Legend Development
Davis Polk advised Mr. David Chow (Co-Chairman and Executive Director of Macau Legend), All Landmark Properties Limited and…
Mubadala investment in Reliance Industries’ Reliance Retail Ventures
Davis Polk is advising Reliance Industries Limited and Reliance Retail Ventures Limited in connection with Mubadala…
General Atlantic investment in Reliance Industries’ Reliance Retail Ventures
Davis Polk is advising Reliance Industries Limited and Reliance Retail Ventures Limited in connection with General Atlantic…
Tencent going-private transaction of Sogou
Davis Polk is advising Tencent Holdings Limited and its affiliates in connection with the going-private transaction of Sogou…
KKR investment in Reliance Industries’ Reliance Retail Ventures
Davis Polk is advising Reliance Industries Limited and Reliance Retail Ventures Limited in connection with KKR’s investment…
Gilead Sciences $21 billion acquisition of Immunomedics
Davis Polk is advising Gilead Sciences, Inc. in its acquisition of Immunomedics, Inc. for $88.00 per share in cash. The…
NYSE asks SEC to lift stay of NYSE’s direct listing rule changes
On September 4, 2020, Davis Polk filed a motion with the Securities and Exchange Commission (the “SEC” or “Commission”) on…
Silver Lake investment in Reliance Industries’ Reliance Retail Ventures
Davis Polk is advising Reliance Industries Limited and Reliance Retail Ventures Limited in connection with Silver Lake’s…